

# Datasheet for ABIN3031504

# anti-ISG15 antibody (AA 72-99)

2 Images



Go to Product page

| _ |     |    |     |
|---|-----|----|-----|
|   | Ve. | rv | iew |

| OVEIVIEW             |  |  |
|----------------------|--|--|
| Quantity:            | 0.4 mL   |  |
| Target:              | ISG15  |  |
| Binding Specificity: | AA 72-99   |  |
| Reactivity:          | Human  |  |
| Host:                | Rabbit   |  |
| Clonality:           | Polyclonal   |  |
| Conjugate:           | This ISG15 antibody is un-conjugated   |  |
| Application:         | Western Blotting (WB), ELISA   |  |
| Product Details      |  |  |
| Immunogen:           | A portion of amino acids 72-99 from the human protein was used as the immunogen for this   |  |
|                      | ISG15 antibody.  |  |
| Isotype:             | Ig Fraction  |  |
| Purification:        | Purified   |  |
| Target Details       |  |  |
| Target:              | ISG15  |  |
| Alternative Name:    | ISG15 (ISG15 Products)   |  |
| Background:          | ISG15 is secreted from monocytes in response to type I interferons and causes natural killer   |  |
|                      |  |  |
|                      | (NK)-cell proliferation and an augmentation of non-MCH (major histocompatibility complex)- restricted cytotoxicity. Synthesis is stimulated by IFN-alpha or IFN-beta or IFN-omega, but not |  |

IFN-gamma . ISG15 expression is also induced by overexpression of interferon regulatory factors that participate in transcriptional regulation of IFN genes, and by influenza B virus. ISG15 is secreted also by cell lines of monocyte, T-lymphocyte, B-lymphocyte, human fibroblasts, and epithelial origins. The induction of terminal differentiation in human melanoma cells is associated with alterations in ISG15 expression. Enhancement of NK cell proliferation, augmentation of non-major histocompatibility complex-restricted cytotoxicity, and induction of IFN-gamma from T cells identify ISG15 as a member of the cytokine cascade and suggest that it may be responsible for amplifying and directing some of the immunomodulatory effects of IFN-alpha or IFN-beta. ISG15 has has also been shown to function intracellularly as a ubiquitin homolog.

UniProt:


P05161

## **Application Details**

| Application Notes: | Titration of the ISG15 antibody may be required due to differences in protocols and |  |
|--------------------|---|--|
|                    | secondary/substrate sensitivity.\. Western blot: 1:1000                             |  |
| Restrictions:      | For Research Use only   |  |

#### Handling

| Format:            | Liquid   |  |
|--------------------|--|--|
| Buffer:            | In 1X PBS pH 7.4 with 0.09 % sodium azide  |  |
| Preservative:      | Sodium azide   |  |
| Precaution of Use: | This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |  |
| Storage:           | -20 °C   |  |
| Storage Comment:   | Aliquot the ISG15 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.                     |  |



### **Western Blotting**

**Image 1.** Western blot analysis of ISG15 antibody and 293 cell lysate (2 ug/lane) either nontransfected (Lane 1) or transfected with ISG15 gene (2).

### **Western Blotting**

**Image 2.** Western blot analysis of ISG15 antibody and 293 cell lysate (2 ug/lane) either nontransfected (Lane 1) or transfected with ISG15 gene (2).